Are we underestimating the lifelong benefits of therapy for obstructive sleep apnea?

Alec M Berman, Saurabh S Thosar, Steven A SheaOregon Institute of Occupational Health Sciences, Oregon Health and Science University, Portland, OR, USAObstructive sleep apnea (OSA) is a complex disorder involving the cardiovascular (CV), pulmonary, and metabolic systems. Characterized by marked dayt...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Berman AM, Thosar SS, Shea SA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	obstructive sleep apnea therapy Psychiatry RC435-571 Neurophysiology and neuropsychology QP351-495
Acceso en línea:	https://doaj.org/article/8c8183cd46954d2d96c769323c208840
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8c8183cd46954d2d96c769323c208840
record_format	dspace
spelling	oai:doaj.org-article:8c8183cd46954d2d96c769323c2088402021-12-02T00:05:26ZAre we underestimating the lifelong benefits of therapy for obstructive sleep apnea?1179-1608https://doaj.org/article/8c8183cd46954d2d96c769323c2088402016-03-01T00:00:00Zhttps://www.dovepress.com/are-we-underestimating-the-lifelong-benefits-of-therapy-for-obstructiv-peer-reviewed-article-NSShttps://doaj.org/toc/1179-1608Alec M Berman, Saurabh S Thosar, Steven A SheaOregon Institute of Occupational Health Sciences, Oregon Health and Science University, Portland, OR, USAObstructive sleep apnea (OSA) is a complex disorder involving the cardiovascular (CV), pulmonary, and metabolic systems. Characterized by marked daytime fatigue and reduced quality of life, OSA is independently associated with increased risk of hypertension,1 cardiovascular disease (CVD),2 including myocardial infarction (MI)3 and ischemic stroke,4 metabolic syndrome,5 and all-cause mortality.6 Currently, the most common treatment for OSA is continuous positive airway pressure (CPAP) during sleep, though its efficacy in reducing daytime fatigue and CVD risk factors depends largely on compliance to therapy, which is poor in the general population.7 Lamberts et al8 performed a large epidemiological study of OSA, using the Danish National Patient Registry (NPR; &sim;4.5 million; including 25,389 people diagnosed with OSA), which confirmed associations between OSA and risk of ischemic stroke and MI. Yet, that study failed to show that CPAP reduces the incidence of these adverse CV events.8 On the other hand, a more recent study, which examined the same Danish NPR across a very similar time period, revealed that in people with OSA, CPAP reduces all-cause mortality.9 This editorial evaluates these seemingly conflicting results, whereby CPAP appears to reduce mortality but not two of the largest contributors to mortality: stroke and MI.Berman AMThosar SSShea SADove Medical Pressarticleobstructive sleep apneatherapyPsychiatryRC435-571Neurophysiology and neuropsychologyQP351-495ENNature and Science of Sleep, Vol 2016, Iss Issue 1, Pp 87-89 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	obstructive sleep apnea therapy Psychiatry RC435-571 Neurophysiology and neuropsychology QP351-495
spellingShingle	obstructive sleep apnea therapy Psychiatry RC435-571 Neurophysiology and neuropsychology QP351-495 Berman AM Thosar SS Shea SA Are we underestimating the lifelong benefits of therapy for obstructive sleep apnea?
description	Alec M Berman, Saurabh S Thosar, Steven A SheaOregon Institute of Occupational Health Sciences, Oregon Health and Science University, Portland, OR, USAObstructive sleep apnea (OSA) is a complex disorder involving the cardiovascular (CV), pulmonary, and metabolic systems. Characterized by marked daytime fatigue and reduced quality of life, OSA is independently associated with increased risk of hypertension,1 cardiovascular disease (CVD),2 including myocardial infarction (MI)3 and ischemic stroke,4 metabolic syndrome,5 and all-cause mortality.6 Currently, the most common treatment for OSA is continuous positive airway pressure (CPAP) during sleep, though its efficacy in reducing daytime fatigue and CVD risk factors depends largely on compliance to therapy, which is poor in the general population.7 Lamberts et al8 performed a large epidemiological study of OSA, using the Danish National Patient Registry (NPR; &sim;4.5 million; including 25,389 people diagnosed with OSA), which confirmed associations between OSA and risk of ischemic stroke and MI. Yet, that study failed to show that CPAP reduces the incidence of these adverse CV events.8 On the other hand, a more recent study, which examined the same Danish NPR across a very similar time period, revealed that in people with OSA, CPAP reduces all-cause mortality.9 This editorial evaluates these seemingly conflicting results, whereby CPAP appears to reduce mortality but not two of the largest contributors to mortality: stroke and MI.
format	article
author	Berman AM Thosar SS Shea SA
author_facet	Berman AM Thosar SS Shea SA
author_sort	Berman AM
title	Are we underestimating the lifelong benefits of therapy for obstructive sleep apnea?
title_short	Are we underestimating the lifelong benefits of therapy for obstructive sleep apnea?
title_full	Are we underestimating the lifelong benefits of therapy for obstructive sleep apnea?
title_fullStr	Are we underestimating the lifelong benefits of therapy for obstructive sleep apnea?
title_full_unstemmed	Are we underestimating the lifelong benefits of therapy for obstructive sleep apnea?
title_sort	are we underestimating the lifelong benefits of therapy for obstructive sleep apnea?
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/8c8183cd46954d2d96c769323c208840
work_keys_str_mv	AT bermanam areweunderestimatingthelifelongbenefitsoftherapyforobstructivesleepapnea AT thosarss areweunderestimatingthelifelongbenefitsoftherapyforobstructivesleepapnea AT sheasa areweunderestimatingthelifelongbenefitsoftherapyforobstructivesleepapnea
_version_	1718403941408964608

Are we underestimating the lifelong benefits of therapy for obstructive sleep apnea?

Ejemplares similares